NasdaqGS:PODDMedical Equipment
Strong Revenue Growth And Upbeat 2026 Outlook Might Change The Case For Investing In Insulet (PODD)
In February 2026, Insulet Corporation reported fourth-quarter 2025 sales of US$783.8 million and full-year revenue of US$2.71 billion, with annual net income of US$247.1 million and diluted earnings per share from continuing operations of US$3.48.
Despite full-year profit declining versus the prior year, Insulet paired strong top-line growth with an outlook for GAAP revenue growth of 21%–23% in the first quarter and 27%–29% for 2026, while confirming that it completed a modest US$59.64...